Crystal Clear: Controls are not enough

The case for sustainable education for pharma operators

It is always the same story. Regardless of how far we advance technologically in the world of aseptic processing and medicine, inspection trends remain flat, and warning letters and costly remediations keep chugging along.  

The challenges involved in trying to avoid this not-inevitable fate never seem to be fully and sustainably addressed. 

It is essential and achievable to ensure:

  • Sterility of the finished product
  • Accuracy in filling volume/amount
  • Contemporaneous documentation

Rapid containment, and prevention of contaminants in the environment in which these lifesaving products are produced is essential.

Controls are not enough. One key ingredient is missing and we all know it: Quality and sustainable education of our operators. 

Conventional on-the-job training teaches our operators what they need to do, but the “why” is rarely taught or understood. From understanding the principles of “first air” (maintaining the unidirectional flow of the air stream leaving the HEPA filters by walking and moving with purpose) to proper hygiene to principles of gowning, the “why” is very important. Teaching the “why” elevates the training to education. 

The need is obvious, so QxP and I created Virtuosi (, a comprehensive on-demand training and education program with courses led by industry veterans. 

Virtuosi delivers an in-depth approach that provides clarity, confidence, and consistency in your operation, no matter where your operators are located in the world. 

It is essential, and achievable, to release quality products to the patient the first time and every time.  Let me know if you have any questions. 

To learn more about why the experts at QxP developed Virtuosi, go to QxP founder Crystal Mersh's blog, "Crystal Clear: Controls are not enough."

QxP Founder and CEO Crystal Mersh’s career in pharma quality has spanned three decades and huge companies. Prior to founding QxP in 2012, Crystal has worked in leadership roles at Mylan, Novartis, Watson Pharmaceuticals, and Sanofi.

Cost Of Quality: Worth Every Cent In Bio/Pharmaceutical Manufacturing

Crystal Mersh
May 24, 2023

Pharmaceutical Quality is NOT a Spectator Sport

Mike Levitt
May 22, 2023

The Six Keys for Effective Deviation Investigators

Mike Levitt
May 18, 2023

There Has to be a Better Way to Train

Tyler DeWitt, Ph.D.
May 15, 2023

Cell and Gene: Article Series on CGT’s Key Drivers

Mark Roache
May 8, 2023

Bacterial Endotoxin Testing is on the Move

Christine Feaster
May 5, 2023

Top 20 Pharma Company Chooses QxP Virtuosi® Platform

Vanessa Figueroa
May 3, 2023

Crystal Clear: Controls are not enough

Crystal Mersh
April 22, 2023

Myth #1: Complying with Regulations and Product Specifications

Brian Duncan
April 20, 2023

Myth #2: Proactively Remediating Bad Inspection Outcomes: What’s the benefit?

Brian Duncan
April 20, 2023

Is it Time to Outsource Internal Auditing?

Mike Levitt
April 18, 2023

Quality is Number One, Even When Trying to Address Supply Chain Issues

Christine Feaster
April 14, 2023

Don’t Be a Daredevil When Retrofitting Your Facility, Part 2

Bob Ferer
April 10, 2023

Don’t Be a Daredevil When Retrofitting Your Facility, Part 1

Bob Ferer
April 10, 2023